Add like
Add dislike
Add to saved papers

A single APOL1 nephropathy variant increases risk of advanced lupus nephritis in Brazilians.

Journal of Rheumatology 2019 November 16
OBJECTIVE: Apolipoprotein L1 gene (APOL1) G1 and G2 renal-risk alleles (RRAs) are associated with end-stage renal disease (ESRD) in blacks with lupus nephritis (LN). The present study determined frequencies of APOL1 RRAs in non-white Brazilian patients with LN and controls to assess association with renal outcomes.

METHODS: APOL1 RRAs were genotyped in 222 healthy blood donors (controls) and 201 cases with LN from three outpatient clinics. Two single nucleotide polymorphisms in the G1 (rs73885319; rs60910145) and an indel for the G2 (rs71785313) variant were genotyped.

RESULTS: The frequency of APOL1 RRAs in non-white Brazilian LN cases did not differ significantly from healthy controls, few participants had 2 RRAs. In the sample, 84.6% of LN cases and 82.9% of controls had 0 RRAs, 13.4% and 15.3% had 1 RRA, and 2.0% and 0.4% had 2 RRAs, respectively. LN cases with >1 APOL1 RRAs had similar baseline characteristics and renal responses to treatment, yet faced higher risk for progressive chronic kidney disease (CKD) to an eGFR <30 ml/min/1.732 compared to those with 0 RRAs (11.1% with 0, 29.6% with 1; 50% with 2 RRAs, p=0.005). Although glomerular lesions and activity scores on initial kidney biopsy did not differ significantly between individuals based on APOL1 genotype, chronicity scores, tubular atrophy and interstitial fibrosis were more severe in those with >1 RRA.

CONCLUSION: Although initial kidney lesions and treatment responses were similar, a single APOL1 RRA in non-white Brazilians with LN was associated with increased risk of advanced CKD and possibly more tubulo-interstitial damage.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app